Study: Breakthrough designated drugs led to better clinical outcomes for patients with NSCLC - Regulatory Focus

Drugs granted a breakthrough therapy designation (BTD) by the US Food and Drug Administration (FDA) were more likely to yield better outcomes for patients with non-small cell lung cancer (NSCLC) compared with drugs that didn’t carry the designation, according…

RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet … [+4294 chars]

full article...